Yondelis (Trabectedin)
trabectedin 1 mg injection, 1 vial · INJECTION · PBS code 13348M
STREAMLINEDWhat it costs
AU$809.22 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2023-08-01.
- • Repeats: 3.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Advanced (unresectable and/or metastatic) leiomyosarcoma or liposarcoma
Initial treatment
Patient must have an ECOG performance status of 2 or less; AND
Patient must have received prior chemotherapy treatment including an anthracycline; AND
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND
The condition must be one of the following subtypes for patients with liposarcoma: (i) dedifferentiated, (ii) myxoid, (iii) round-cell, (iv) pleomorphic.
This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.
Sponsor: Specialised Therapeutics Pharma Pty Ltd ABN 77 609 261 430
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.